Search

Search Constraints

You searched for: Author/Creator Varghese, Shiji

Search Results

1. [P1–416]: CSF TOTAL TAU AS A BIOMARKER FOR NEURONAL INJURY IN ALZHEIMER's DISEASE: ALIGNING RATES OF CSF CHANGE WITH RATES OF HIPPOCAMPAL AND CORTICAL GRAY MATTER ATROPHY. (1st July 2017)

2. A pilot study of the utility of cerebrospinal fluid neurofilament light chain in differentiating neurodegenerative from psychiatric disorders: A 'C-reactive protein' for psychiatrists and neurologists?. (January 2020)

3. Cerebrospinal fluid lysosomal enzymes and alpha‐synuclein in Parkinson's disease. Issue 8 (16th January 2014)

4. Cerebrospinal fluid neurofilament light chain differentiates primary psychiatric disorders from rapidly progressive, Alzheimer's disease and frontotemporal disorders in clinical settings. Issue 11 (1st February 2022)

5. Cerebrospinal fluid neurofilament light chain is elevated in Niemann–Pick type C compared to psychiatric disorders and healthy controls and may be a marker of treatment response. (June 2020)

6. CSF Tau supplements 14-3-3 protein detection for sporadic Creutzfeldt–Jakob disease diagnosis while transitioning to next generation diagnostics. (April 2018)

7. Longitudinal changes in CSF alpha‐synuclein species reflect Parkinson's disease progression. Issue 10 (6th October 2016)

8. Neurofilament light chain in psychiatric and neurodegenerative disorders: A 'c‐reactive protein' for the brain?: Biomarkers (non‐neuroimaging) / plasma/serum/urine biomarkers. (7th December 2020)

9. O4‐11‐05: The correlation between ß‐amyloid PET‐imaging and cerebrospinal fluid biomarkers is affected by the assay design. (1st July 2015)

10. Oligomeric and phosphorylated alpha-synuclein as potential CSF biomarkers for Parkinson's disease. Issue 1 (December 2016)